COMPANY PROFILE

Cleveland Diagnostics

Explore full profile

Developing cancer diagnostics that are simpler and clearer

Cleveland, United StatesFounded 2013Biotech & Life Sciences

Valuation $250–500M Last recorded · 2024

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Cleveland Diagnostics

Cleveland Diagnostics is a pioneering company in the healthcare sector, specializing in the development of advanced diagnostic technologies aimed at early cancer detection. The company serves healthcare providers, research institutions, and potentially patients directly. Operating in the medical diagnostics market, Cleveland Diagnostics focuses on creating tests that identify cancer at its earliest stages, significantly increasing the chances of successful treatment and survival. The business model revolves around the development and commercialization of proprietary diagnostic tests, which are sold to healthcare providers and institutions. Revenue is generated through the sale of these diagnostic tests and potentially through partnerships or licensing agreements with other healthcare entities. The company leverages its proprietary technology to separate protein isoforms, which enhances the accuracy and reliability of cancer detection. This innovative approach addresses the critical need for effective early detection methods, aiming to improve patient outcomes and reduce healthcare costs associated with late-stage cancer treatments.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2013
Headquarters: Cleveland, United States
Employees: 108
Open positions: 15
Dealroom signal: 87.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Biomarkers, Health Diagnostics, Spinout, proteomics, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

8 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Oct 2025	$0	—	Undisclosed	↗
DEBTDebt	Jan 2024	$0	—	Symbolic Capital	↗

Showing the latest 2 of 8 recorded eventsBook a demo for the full funding history →

Growth signals

Cleveland Diagnostics website traffic

Latest recorded traffic for Cleveland Diagnostics is 2.8K monthly website visits, down 58.2% over the last three months. Cleveland Diagnostics's team grew 45.9% over the past year.

Latest monthly visits2.8K 3-month web change-58.2% 1-year team growth+45.9%

Monthly website visitsJan 2021–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Vice President of FinanceCleveland, Ohio, United States, Northern America, Americas · Finance · Sep 5, 2026 Field Applications Specialist (REMOTE)Cleveland, Ohio, United States, Northern America, Americas · Other · Aug 31, 2026 Field Applications Specialist (REMOTE)3615 Superior Ave, Cleveland, OH 44114, USA · Other · Aug 27, 2026 Manufacturing AssociateCleveland, OH · Other · Aug 18, 2026 Sr. HCP Marketing Manager, IsoPSACleveland, Ohio, United States, Northern America, Americas · Marketing & Communication · Aug 15, 2026 Senior Director of Regulatory AffairsCleveland, OH · Full-Stack Development · Aug 12, 2026 Finance and Administrative AssistantCleveland, OH · Finance · Jul 28, 2026 IT Helpdesk TechnicianCleveland, OH · Other · Jul 22, 2026

8 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational	2	$165K	$1.6M
RORadionetics OncologyRadionetics Oncology is a precision oncology company focusing on the discovery and development of radiopharmaceuticals	San Diego, United States	Operational
GEGENECASTUltra-sensitive liquid biopsy technology for early cancer detection and monitoring, enhancing diagnosis and treatment outcomes	Seoul, South Korea	Operational
INInbiomotionA personalized medicine company developing biomarkers that can predict bone metastasis in cancers	Barcelona, Spain	Operational
PAPairidexPCR assay for personalized blood cancer detection	St. Louis, United States	Operational
PBProseek BioNovel biomarker driven blood tests enabling early ovarian cancer detection	Brisbane, Australia	Operational
EOEpi OneDeveloping a groundbreaking cancer diagnosis platform for early detection, prognosis, and post-diagnosis drug response prediction	New York City, United States	Operational
HUHunaWe are committed to making early cancer detection	Brazil	Operational